ARTICLE | Clinical News

Eisai, Purdue's lemborexant meets in Phase III for insomnia

March 16, 2018 6:43 PM UTC

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase III SUNRISE 1 trial in about 1,000 patients ages 55 and older with insomnia showing that oral lemborexant (E2006) given each night before bedtime met the primary endpoint of improving Latency to Persistent Sleep (LPS) vs. both placebo and zolpidem ER. Lemborexant also met the secondary endpoints of improving sleep efficiency and Wake After Sleep Onset (WASO) vs. both placebo and zolpidem ER.

The partners plan to present full data from the double-blind, international trial at an upcoming medical meeting this year...